Most Popular
-
1
10-man S. Korea lose to Indonesia to miss out on Paris Olympic football qualification
-
2
Hybe-Ador feud should have limited effect on Hybe's overall performance: analysts
-
3
Second Gimpo civil servant found dead, after apologizing for not finishing work
-
4
DP leader says he will meet Yoon without conditions
-
5
First-ever meeting of president, opposition chief set to finally happen
-
6
NewJeans' singles, Japanese debut to proceed as planned, despite Hybe-Ador feud
-
7
Experts raise concerns about Japan putting pressure on Naver over Line
-
8
Samsung mobile chief, Google device head meet in Seoul
-
9
Ship linked to NK arms shipments to Russia is moored in China: State Dept.
-
10
[Kim So-hyun] The quiet taxi driver from Paris
![[Kim So-hyun] The quiet taxi driver from Paris](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/25/20240425050891_0.jpg&u=)
![[Kim So-hyun] The quiet taxi driver from Paris](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/25/20240425050891_0.jpg&u=)
[THE INVESTOR] LG Life Science announced on Sept. 1 that it is releasing two kinds of fillers containing lidocaine, a local anesthesia, in China.
The biopharmaceutical arm of LG is launching Yvoire Classic Plus and Yvoire Volume Plus, dermal wrinkle fillers equipped with the solution to relieve pain upon administration.
LG has won approval for sales from China Food and Drug Administration in April, the first for an imported filler containing lidocaine.
The South Korean company’s dermal filler range has posted 18.5 billion won (US$16.51 million) in sales in the second quarter of this year, doubling from the same period last year. About 75 percent of the sales came from exports, with China being its main market.
By Hwang You-mee (glamazon@heraldcorp.com)
The biopharmaceutical arm of LG is launching Yvoire Classic Plus and Yvoire Volume Plus, dermal wrinkle fillers equipped with the solution to relieve pain upon administration.
LG has won approval for sales from China Food and Drug Administration in April, the first for an imported filler containing lidocaine.
The South Korean company’s dermal filler range has posted 18.5 billion won (US$16.51 million) in sales in the second quarter of this year, doubling from the same period last year. About 75 percent of the sales came from exports, with China being its main market.
By Hwang You-mee (glamazon@heraldcorp.com)
